
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists improve blood sugar control by triggering greater insulin release and by reducing how much glucose the liver adds to the bloodstream. They are widely used when traditional oral diabetes medications, including metformin, are not enough on their own. Research has also shown that certain GLP-1 agonists can decrease the risk of serious cardiovascular outcomes in people living with type 2 diabetes and diagnosed heart disease.
For those who do not have diabetes, GLP-1 agonists including Wegovy and Saxenda are FDA approved treatments aimed at helping with weight loss. They work by strengthening fullness signals and decreasing appetite, allowing patients to eat less while feeling more comfortably satisfied. Studies have demonstrated that when GLP-1 therapy is used alongside lifestyle changes, many patients achieve significant and durable weight loss.
GLP-1 receptor agonists control blood sugar by promoting insulin release after meals and limiting glucagon, the hormone that signals the liver to add more glucose to the blood. This two sided mechanism reduces sharp spikes in blood glucose and supports better daily control. Because they work in a glucose dependent way, they are less likely to cause low blood sugar compared with many older diabetes therapies.
One key reason GLP-1 therapy has gained so much attention is its ability to help with long term weight loss and weight control. By slowing gastric emptying and interacting with the brain to strengthen feelings of fullness, GLP-1 medications reduce appetite and make it easier for individuals to lower their calorie intake without feeling deprived. Clinical studies have shown that medications such as liraglutide, semaglutide, and tirzepatide can achieve considerable and sustained weight loss when combined with appropriate lifestyle interventions.



GLP-1/GIP co-agonists bind to and activate both GLP-1 and GIP receptors, delivering stronger effects on insulin secretion and appetite control than therapies focused on GLP-1 alone. By influencing multiple metabolic pathways, these medications provide a more comprehensive way to manage blood sugar and hunger, making them promising treatments for obesity and type 2 diabetes.
GLP-1/glucagon co-agonists act upon both GLP-1 and glucagon receptors to enhance weight loss and energy use, helping patients burn fat while preserving lean muscle mass.

